WallStSmart

VTEX (VTEX)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 8% more annual revenue ($258.90M vs $240.52M). VTEX leads profitability with a 8.3% profit margin vs -15.5%. VTEX earns a higher WallStSmart Score of 52/100 (C-).

VTEX

Buy

52

out of 100

Grade: C-

Growth: 8.0Profit: 6.5Value: 6.3Quality: 5.0

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

VTEXUndervalued (+75.8%)

Margin of Safety

+75.8%

Fair Value

$12.80

Current Price

$3.76

$9.04 discount

UndervaluedFair: $12.80Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

VTEX2 strengths · Avg: 9.0/10
EPS GrowthGrowth
54.2%10/10

Earnings expanding 54.2% YoY

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

VTEX2 concerns · Avg: 3.5/10
P/E RatioValuation
36.3x4/10

Premium valuation, high expectations priced in

Market CapQuality
$680.24M3/10

Smaller company, higher risk/reward

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : VTEX

The strongest argument for VTEX centers on EPS Growth, Price/Book. Revenue growth of 10.5% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : VTEX

The primary concerns for VTEX are P/E Ratio, Market Cap.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

VTEX profiles as a value stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SOFTWARE - APPLICATION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VTEX scores higher overall (52/100 vs 41/100) and 10.5% revenue growth. ZEPP offers better value entry with a 48.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

VTEX

TECHNOLOGY · SOFTWARE - APPLICATION · USA

VTEX provides a software-as-a-service digital commerce platform for business brands and retailers. The company is headquartered in London, the United Kingdom.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?